Met in urological cancers

Cancers

Volumn 6, Issue 4, 2014, Pages 2387-2403

  Miyata, Yasuyoshi ^a   Asai, Akihiro ^a   Mitsunari, Kensuke ^a   Matsuo, Tomohiro ^a   Ohba, Kojiro ^a   Mochizuki, Yasushi ^a   Sakai, Hideki ^a  

^a NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Met; Pathological features; Prostate cancer; Renal cell carcinoma; Survival; Target therapy; Urothelial cancer

Indexed keywords

ABIRATERONE; CABOZANTINIB; CRIZOTINIB; DOCETAXEL; EMIBETUZUMAB; ENZALUTAMIDE; FORETINIB; GOLVATINIB; MGCD 265; MITOXANTRONE; MONOCLONAL ANTIBODY; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; ONARTUZUMAB; PLACEBO; PREDNISONE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TIVANTINIB; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; BLADDER CANCER; CANCER CELL LINE; CANCER PROGNOSIS; CARCINOGENESIS; CASTRATION RESISTANT PROSTATE CANCER; DECREASED APPETITE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TREATMENT FAILURE; FATIGUE; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG EMBOLISM; MOLECULARLY TARGETED THERAPY; NAUSEA; NONHUMAN; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEINURIA; REVIEW; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; URINARY TRACT CANCER; VOMITING;

EID: 84938869876     PISSN: None     EISSN: 20726694     Source Type: Journal    
DOI: 10.3390/cancers6042387     Document Type: Review

References (84)

1. Cooper, C.S.; Park, M.; Blair, D.G.; Tainsky, M.A.; Huebner, K.; Croce, C.M.; Vande Woude, G.F. Molecular cloning of a new transforming gene from a chemically transformed human cell line. Nature1984, 311, 29–33.
2. Birchmeier, C.; Birchmeier, W.; Gherardi, E.; Vande Wounde, G.F. Met, metastasis, mortality and more. Nat. Rev. Mol. Cell Biol.2003, 4, 915–925.
3. Trusolino, L.; Bertotti, A.; Comoglio, P.M. MET signaling: Principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol.2010, 11, 834–848.
4. Bussolino, F.; di Renzo, M.F.; Ziche, M.; Bocchietto, E.; Olivero, M.; Naldini, L.; Gaudino, G.; Tamagnone, L.; Coffer, A.; Comoglio, P.M. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth. J. Cell Biol.1992, 119, 629–641.
5. Kagoshima, M.; Kinoshita, T.; Matsumoto, K.; Nakamura, T. Developmental changes in hepatocyte growth factor mRNA and its receptor in rat liver, kidney and lung. Eur. J. Biochem.1992, 210, 375–380.
6. Yano, S.; Nakagawa, T. The current state of molecularly targeted drugs tragting HGF/Met. Jpn. J. Clin. Oncol.2014, 44, 9–12.
7. Scagliotti, G.V.; Novello, S.; von Pawel, J. The emerging role of MET/HGF inhibitors in oncology. Cancer Treat. Rev.2013, 39, 793–801.
8. Koeppen, H.; Rost, S.; Yauch, R. Developing biomarkers to predict benefit from HGF/MET pathway inhibitors. J. Pathol.2014, 232, 210–218.
9. Lubensky, I.A.; Schmidt, L.; Zhuang, Z.; Weirich, G.; Pack, S.; Zambrano, N.; Walther, M.M.; Choyke, P.; Linehan, W.M.; Zbar, B. Hereditary and sporadic papillary renal cell carcinoma with c-met mutations share a distinct morphological phenotype. Am. J. Pathol.1999, 155, 517–526.
10. Park, W.S.; Dong, S.M.; Kim, S.Y.; Na, E.Y.; Shin, M.S.; Pi, J.H.; Kim, B.J.; Bae, J.H.; Hong, Y.K.; Lee, K.S. et al. Somatic mutations in the kinase domain of the Met/hepatocyte growth factor receptor gene in childhood hepatocellular carcinomas. Cancer Res. 1999, 59, 307–310.
11. Toschi, L.; Cappuzzo, F. Clinical implications of MET gene copy number in lung cancer. Future Oncol. 2010, 6, 239–247.
12. Grant, D.S.; Kleinman, H.K.; Goldberg, I.D.; Bhargava, M.M.; Nickoloff, B.J.; Kinsella, J.L.; Polverini, P.; Rosen, E.M. Scatter factor induces blood vessel formation in vivo. Proc. Natl. Acad. Sci. USA1993, 90, 1937–1941.
13. Zhang, Y.W.; Su, Y.; Volpert, O.V.; Vande Wounde, G.F. Hepatocyte growth factor/scatter factor mediates angiogenesis through positive VEGF and negative thrombospondin 1 regulation. Proc. Natl. Acad. Sci. USA2003, 100, 12718–12723.
14. Delitto, D.; Vertes-George, E.; Hughes, S.J.; Behrns, K.E.; Trevino, J.G. c-Met signaling in the development of tumorgenesis and chemoresitance: Potential applications in pancreatic cancer. World J. Gastroentrol.2014, 20, 8458–8470.
15. Peng, Y.; Guo, J.J.; Liu, Y.M.; Wu, X.L. MicroRNA-34A inhibits the growth, invasion and metastasis of gastric cancer by targeting PDGFR and MET expression. Biosci. Rep.2014, 34, 247–256.
16. Ueki, R.; Sando, S. A DNA adaptor to c-Met inhibits cancer cell migration. Chem. Commun.2014, 50, 13131–13134.
17. Siegel, R.; Naishadham, D.; Jemal, A. Cancer statistics, 2013. CA Cancer J. Clin.2013, 63, 11–30.
18. Yue, D.; Wang, Y.; Ma, P.; Li, Y.Y.; Chen, H.; Wang, P.; Ren, C.S. Effects of transferred NK4 gene on proliferation, migration, invasion and apoptosis of human prostate cancer DU145 cells. Asian J. Androl.2010, 12, 381–389.
19. Sankpal, U.T.; Abdelrahim, M.; Connelly, S.F.; Lee, C.M.; Madero-Visbal, R.; Colon, J.; Smith, J.; Safe, S.; Maliakal, P.; Basha, R. Small molecule tolfenamic acid inhibits PC-3 cell proliferation and invasion in vitro, and tumor growth in orthotopic mouse model for prostate cancer. Prostate2012, 72, 1648–1658.
20. Nishida, S.; Hirohashi, Y.; Torigoe, T.; Inoue, R.; Kitamura, H.; Tanaka, T.; Takahashi, A.; Asanuma, H.; Masumori, N.; Tsukamoto, T. et al. Prostate cancer stem-like cells/cancer-initiating cells have an autocrine system of hepatocyte growth factor. Cancer Sci. 2013, 104, 431–436.
21. Hagman, Z.; Haflidadottir, B.S.; Ansari, M.; Persson, M.; Bjartell, A.; Edsjö, A.; Ceder, Y. The tumour suppressor miR-34c targets MET in prostate cancer cells. Br. J. Cancer2013, 109, 1271–1278.
22. Niu, Y.; Altuwaijri, S.; Lai, K.P.; Wu, C.T.; Ricke, W.A.; Messing, E.M.; Yao, J.; Yeh, S.; Chang, C. Androgen receptor is a tumor suppressor and proliferator in prostate cancer. Proc. Natl. Acad. Sci. USA2008, 105, 12182–12187.
23. Verras, M.; Lee, J.; Xue, H.; Li, T.H.; Wang, Y.; Sun, Z. The androgen receptor negatively regulates the expression of c-Met: Implications for a novel mechanism of prostate cancer progression. Cancer Res. 2007, 67, 967–975.
24. Liu, T.; Mendes, D.E.; Berkman, C.E. From AR to c-Met: Androgen deprivation leads to a signaling pathway switch in prostate cancer cells. Int. J. Oncol.2013, 43, 1125–1130.
25. Knudsen, B.S.; Edlund, M. Prostate cancer and the met hepatocyte growth factor receptor. Adv. Cancer Res.2004, 91, 31–67.
26. Tu, W.H.; Zhu, C.; Clark, C.; Christensen, J.G.; Sun, Z. Efficacy of c-Met inhibitor for advanced prostate cancer. BMC Cancer 2010, 10, doi:10.1186/1471-2407-10-556.
27. Guzmán-Ramírez, N.; Völler, M.; Wetterwald, A.; Germann, M.; Cross, N.A.; Rentsch, C.A.; Schalken, J.; Thalmann, G.N.; Cecchini, M.G. In vitro propagation and characterization of neoplastic stem/progenitor-like cells from human prostate cancer tissue. Prostate2009, 69, 1683–1539.
28. Van Leenders, G.J.L.H.; Sookhlall, R.; Teubel, W.J.; de Ridder, C.M.A.; Reneman, S.; Sacchetti, A.; Vissers, K.J.; van Weerden, W.; Jenster, G. Activation of c-MET induces a stem-like phenotype in human prostate cancer. PLoS One2011, 6, e26753.
29. Pisters, L.L.; Troncoso, P.; Zhau, H.E.; Li, W.; von Eschenbach, A.C.; Chung, L.W. c-Met proto-oncogene expression in benign and malignant human prostate tissues. J. Urol. 1995, 154, 293–298.
30. Humphrey, P.A.; Zhu, X.; Zarnegar, R.; Swanson, P.E.; Ratliff, T.L.; Vollmer, R.T.; Day, M.L.; Hepatocyte growth factor and its receptor (c-MET) in prostatic carcinoma. Am. J. Pathol. 1995, 147, 386–396.
31. Watanabe, M.; Fukutome, K.; Kato, H.; Murata, M.; Kawamura, J.; Shiraishi, T.; Yatani, R. Progression-linked overexpression of c-Met in prostatic intraepithelial neoplasia and latent as well as clinical prostate cancers. Cancer Lett. 1999, 141, 173–178.
32. Knudsen, B.S.; Gmyrek, G.A.; Inra, J.; Scherr, D.S.; Vaughan, E.D.; Nanus, D.M.; Kattan, M.W.; Gerald, WL.; Vande Woude, G.F. High expression of the Met receptor in prostate cancer metastasis to bone. Urology2002, 60, 1113–1117.
33. Strohmeyer, D.; Strauss, F.; Rössing, C.; Roberts, C.; Kaufmann, O.; Bartsch, G.; Effert, P. Expression of bFGF, VEGF and c-met and their correlation with microvessel density and progression in prostate carcinoma. Anticancer Res. 2004, 24, 1797–1804.
34. Jacobsen, F.; Ashtiani, S.N.; Tennstedt, P.; Heinzer, H.; Simon, R.; Sauter, G.; Sirma, H.; Tsourlakis, M.C.; Minner, S.; Schlomm, T. et al. High c-MET expression is frequent but not associated with early PSA recurrence in prostate cancer. Exp. Ther. Med. 2013, 5, 102–106.
35. Pfeiffer, M.J.; Smit, F.P.; Sedelaar, J.P.; Schalken, J.A. Steroidogenic enzymes and stem cell markers are upregulated during androgen deprivation in prostate cancer. Mol. Med. 2011, 17, 657–664.
36. Schimmoller, F.; Zayzafoon, M.; Chung, L.W.K.; Zhau, H.E.; Fagerlund, K.M.; Aftab, D.T. Cabozantinib (XL184), a dual MET-VEGFR2 inhibitor, blocks osteoblastic and osteolytic progression of human prostate cancer xenografts in mouse bone. Mol. Cancer Ther. 2011, 10, A233.
37. Smith, D.C.; Smith, M.R.; Sweeney, C.; Elfiky, A.A.; Logothetis, C.; Corn, P.G.; Vogelzang, N.J.; Small, E.J.; Harzstark, A.L.; Gordon, M.S. et al. Cabozantinib in patients with advanced prostate cancer: Results of a phase II randomized discontinuation trial. J. Clin. Oncol. 2013, 31, 412–419.
38. Yap, T.A.; Olmos, D.; Brunetto, A.T.; Tunariu, N.; Barriuso, J.; Riisnaes, R.; Pope, L.; Clark, J.; Futreal, A.; Germuska, M. et al. Phase I trial of a selective c-MET inhibitor ARQ 197 incorporating proof of mechanism pharmacodynamic studies. J. Clin. Oncol. 2011, 29, 1271–1279.
39. Dahut, W.L.; Scripture, C.; Posadas, E.; Jain, L.; Gulley, J.L.; Arlen, P.M.; Wright, J.J.; Yu, Y.; Cao, L.; Steinberg, S.M. et al. A phase II clinical trial of sorafenib in androgen-independent prostate cancer. Clin. Cancer Res. 2008, 14, 209–214.
40. Michaelson, M.D.; Oudard, S.; Ou, Y.C.; Sengeløv, L.; Saad, F.; Houede, N.; Ostler, P.; Stenzl, A.; Daugaard G; Jones R. et al. Randomized, placebo-controlled, phase III trial of sunitinib plus prednisone versus prednisone alone in progressive, metastatic, castration-resistant prostate cancer. J. Clin. Oncol. 2013, 32, 76–82.
41. Beck, S.D.; Patel, M.I.; Snyder, M.E.; Kattan, M.W.; Motzer, R.J.; Reuter, V.E.; Russo, P. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann. Surg. Oncol.2004, 11, 71–77.
42. Giubellino, A.; Linehan, W.M.; Bottaro, D.P. Targeting the Met signaling pathway in renal cancer. Expert Rev. Anticancer Ther.2009, 9, 785–793.
43. Schmidt, L.; Duh, F.M.; Chen, F.; Kishida, T.; Glenn, G.; Choyke, P.; Scherer, S.W.; Zhuang, Z.; Lubensky, I.; Dean, M. et al. Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet.1997, 16, 68–73.
44. Schmidt, L.; Junker, K.; Weirich, G.; Glenn, G.; Choyke, P.; Lubensky, I.; Zhuang, Z.; Jeffers, M.; Vande, W.G.; Neumann, H. et al. Two North American families with hereditary papillary renal carcinoma and identical novel mutations in the MET protooncogene. Cancer Res. 1998, 58, 1719–1722.
45. Zbar, B.; Tory, K.; Merino, M.; Schmidt, L.; Glenn, G.; Choyke, P.; Walther, M.M.; Lerman, M.; Linehan, W.M. Hereditary papillary renal cell carcinoma. J. Urol.1994, 151, 561–566.
46. Schmidt, L.; Junker, K.; Nakaigawa, N.; Kinjerski, T.; Weirich, G.; Miller, M.; Lubensky, I.; Neumann, H.P.; Brauch, H.; Decker, J. et al. Novel mutations of the MET proto-oncogene in papillary renal carcinomas. Oncogene1999, 18, 2343–2350.
47. Betsunoh, H.; Mukai, S.; Akiyama, Y.; Fukushima, T.; Minamiguchi, N.; Hasui, Y.; Osada, Y.; Kataoka, H. Clinical relevance of hepsin and hepatocyte growth factor activator inhibitor type 2 expression in renal cell carcinoma. Cancer Sci. 2007, 98, 491–498.
48. Choi, J.S.; Kim, M.K.; Seo, J.W.; Choi, Y.L.; Kim, D.H.; Chun, Y.K.; Ko, Y.H. MET expression in sporadic renal cell carcinomas. J. Korea Med. Sci.2006, 21, 672–677.
49. Oh, R.R.; Park, J.Y.; Lee, J.H.; Shin, M.S.; Kim, H.S.; Lee, S.K.; Kim, Y.S.; Lee, S.H.; Lee, S.N.; Yang, Y.M. et al. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas. APMIS2002, 110, 229–238.
50. Peruzzi, B.; Athauda, G.; Bottaro, D.P. The von Hippel-Lindau tumor suppressor gene product represses oncogenic beta-catenin signaling in renal carcinoma cells. Proc. Natl. Acad. Sci. USA2006, 103, 14531–14536.
51. Gilney, G.T.; Aziz, S.A.; Camp, R.L.; Conrad, P.; Schwartz, B.E.; Chen, C.R.; Kelly, W.K.; Kluger, H.M. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma. Ann. Oncol. 2013, 24, 343–349.
52. Miyata, Y.; Sagara, Y.; Kanda, S.; Hayashi, T.; Kanetake, H. Phosphorylated hepatocyte growth factor receptor/c-Met is associated with tumor growth and prognosis in patients with bladder cancer: Correlation with matrix metalloproteinase-2 and -7 and E-cadherin. Hum. Pathol. 2009, 40, 496–504.
53. Eder, J.P.; Shapiro, G.I.; Appleman, L.J.; Zhu, A.X.; Miles, D.; Keer, H.; Cancilla, B.; Chu, F.; Hitchcock-Bryan, S.; Sherman, L. et al. A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2. Clin. Cancer Res.2010, 16, 3507–3516.
54. Choueiri, T.K.; Vaishampayan, U.; Rosenberg, J.E.; Logan, T.F.; Harzstark, A.L.; Bukowski, R.M.; Rini, B.I.; Srinivas, S.; Stein, M.N.; Adams, L.M. et al. A phase II and biomarker study of the dual MET/VEGFR-2 inhibitor foretinib in patients with papillary renal cell cancer. J. Clin. Oncol.2013, 31, 181–186.
55. Garcia, A.; Rosen, L.; Cunningham, C.C.; Nemunaitis, J.; Li, C.; Rulewski, N.; Dovholuk, A.; Savage, R.; Chan, T.; Bukowksi, R. et al. Phase 1 study of ARQ 197, a selective inhibitor of the c-Met RTK in patients with metastatic solid tumors reaches recommended phase 2 dose. J. Clin. Oncol. 2007, 25, Abstract No. 3525.
56. Choueiri, T.K.; Pal, S.K.; McDermott, D.F.; Morrissey, S.; Ferguson, K.C.; Holland, J.; Kaelin, W.G., Jr.; Dutcher, J.P. A phase I study of cabozantinib (XL184) in patients with RCC. Ann. Oncol. 2014, in press.
57. Stein, J.P.; Grossfeld, G.D.; Ginberg, D.A.; Esrig, D.; Freeman, J.A.; Figueroa, A.J.; Skinner, D.; Cote, R. Prognostic markers in bladder cancer: A contemporary review of the literature. J. Urol.1998, 160, 645–659.
58. Allard, P.; Bernard, P.; Frader, Y.; Tetu, B. The early clinical course of primary Ta and T1 bladder cancer: A proposed prognostic index. Br. J. Urol.1998, 81, 692–698.
59. Cheng, H.L.; Trink, B.; Tzai, T.S.; Liu, H.S.; Chan, S.H.; Ho, C.L.; Sidransky, D.; Chow, N.H. Overexpression of c-met as a prognostic indicator for transitional cell carcinoma of the urinary bladder: A comparison with p53 nuclear accumulation. J. Clin. Oncol.2002, 20, 1544-1550.
60. Millán-Rodríguez, F.; Chéchile-Toniolo, G.; Salvador-Bayarri, J.; Palou, J.; Vicente-Rodríguez, J. Multivariate analysis of the prognostic factors of primary superficial bladder cancer. J. Urol.2000, 163, 73-78.
61. Holmang, S.; Hedelin, H.; Anderstrom, C; Johansson, S.L. The relationship among multiple recurrences, progression and prognosis of patients with stages Ta and T1 transitional cell cancer of the bladder followed for at least 20 years. J. Urol.1995, 153, 1823-1827.
62. Crew, J.P.; O’Brien, T.; Bradburn, M.; Fuggle, S.; Bicknell, R.; Cranston, D.; Harris, A.L. Vascular endothelial growth factor is predictor of relapse and stage progression in superficial bladder cancer. Cancer Res. 1997, 57, 5281-5285.
63. Chow, N.H.; Liu, H.S.; Chan, S.H The role of nm23-H1 in the progression of transitional cell bladder cancer. Clin. Cancer Res.2000, 6, 3595-3599.
64. Chow, N.H.; Liu, H.S.; Chan, S.H; Cheng, H.L.; Tzai, T.S. Expression of vascular endothelial growth factor in primary superficial bladder cancer. Anticancer Res. 1999, 19, 4593-4597.
65. Bakkar, A.A.; Wallerand, H; Radvanyi, F.; Lahaye, J.B.; Pissard, S.; Lecerf, L.; Kouyoumdjian, J.C.; Abbou, C.C.; Pairon, J.C.; Jaurand, M.C. et al.FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. Cancer Res. 2003, 63, 8108-8112.
66. Neuzillet, Y.; Paoletti, X.; Ouerhani, S.; Mongiat-Artus, P.; Soliman, H.; de The, H.; Sibony, M.; Denoux, Y.; Molinie, V.; Herault, A. et al.A meta-analysis of the relationship between FGFR3 and TP53 mutations in bladder cancer. PLoS One2012, 7, e48993.
67. Miyata, Y.; Sakai, H. Thrombospondin-1 in urological cancer: Pathological role, clinical significance, and therapeutic prospects. Int. J. Mol. Sci.2013, 14, 12249-12272.
68. Yeh, C.Y.; Shin, S.M.; Yeh, H.H.; Wu, T.J.; Shin, J.W.; Chang, T.Y.; Raghavaraju, G; Lee, C.T.; Chiang, J.H.; Tseng, V.S. et al.Transcriptional activation of the Axl and PDGFR-α by c-Met through a ras- and Src-independent mechanism in human bladder cancer. BMC Cancer2011, doi: 10.1186/1471-2407-11-139.
69. Wang, M.H.; Ronsin, C; Gesnel, M.C.; Coupey, L.; Skeel, A.; Leonard, E.J.; Breathnach, R. Identification of the ron gene product as the receptor for the human macrophage stimulating protein. Science1994, 266, 117-119.
70. Compérat, E.; Roupret, M.; Chartier-Kastler, E.; Bitker, M.O.; Richard, F.; Camparo, P.; Capron, F.; Cussenot, O. Prognostic value of MET, RON and histoprognostic factors for urothelial carcinoma in the upper urinary tract. J. Urol.2008, 179, 868-872.
71. Chen, Q.; Seol, D.W.; Carr, B.; Zarnegar, R. Co-expression and regulation of Met and Ron proto-oncogenes in human hepatocellular carcinoma tissues and cell lines. Hepatology1997, 26, 59-66.
72. Maggiora, P.; Lorenzato, A.; Fracchioli, S.; Costa, B.; Castagnaro, M.; Arisio, R.; Katsaros, D.; Massobrio, M.; Comoglio, P.M.; Flavia di Renzo, M. The RON and MET oncogenes are co-expressed in human ovarian carcinomas and cooperate in activating invasiveness. Exp. Cell. Res.2003, 288, 382-389.
73. Tamatani, T.; Hattori, K.; Iyer, A.; Tamatani, K.; Oyasu, R. Hepatocyte growth factor is an invasion/migration factor of rat urothelial carcinoma cells in vitro. Carcinogenesis1999, 20, 957–962.
74. Wang, P.; Nishitani, M.A.; Tanimoto, S.; Kishimoto, T.; Fukumori, T.; Takahashi, M.; Kanayama, H.O. Bladder cancer cell invasion is enhanced by cross-talk with fibroblasts through hepatocyte growth factor. Urology2007, 69, 780–784.
75. Natali, P.G.; Prat, M.; Nicotra, M.R.; Bigotti, A.; Olivero, M.; Comoglio, P.M.; di Renzo, M.F. Overexpression of the met/HGF receptor in renal cell carcinomas. Int. J. Cancer1996, 69, 212–217.
76. Joseph, A.; Weiss, G.H.; Jin, L.; Fuchs, A.; Chowdhury, S.; O’Shaugnessy, P.; Goldberg, I.D.; Rosen, E.M. Expression of scatter factor in human bladder carcinoma. J. Natl. Cancer Inst.1995, 87, 372–377.
77. Cheng, H.L.; Liu, H.S.; Lin, Y.J.; Chen, H.H.; Hsu, P.Y.; Chang, T.Y.; Ho, C.L.; Tzai, T.S.; Chow, N.H. Co-expression of RON and MET is a prognostic indicator for patients with transitional-cell carcinoma of the bladder. Br. J. Cancer2005, 92, 1906–1914.
78. Sanchez-Carbayo, M.; Socci, N.D.; Lozano, J.J.; Haab, B.B.; Cordon-Cardo, C. Profiling bladder cancer using targeted antibody arrays. Am. J. Pathol.2006, 168, 93–103.
79. Li, B.; Kanamaru, H.; Noriki, S.; Fukuda, M.; Okada, K. Differential expression of hepatocyte growth factor in papillary and nodular tumors of the bladder. Int. J. Urol.1998, 5, 436–440.
80. Millis, S.Z.; Bryant, D.; Basu, G.; Bender, R.; Vranic, S.; Gatalica, Z.; Vogelzang, N.J. Molecular profiling of infiltrating urothelial carcinoma of bladder and nonbladder origin. Clin. Genitourin. Cancer2014, doi:10.1016/j.clgc.2014.07.010.
81. Arena, S.; Pisacane, A.; Mazzone, M.; Comoglio, P.M.; Bardelli, A. Genetic targeting of the kinase activity of the Met receptor in cancer cells. Proc. Natl. Acad. Sci. USA2007, 104, 11412–11417.
82. Parr, C.; Jiang, W.G. Expression of hepatocyte growth factor/scatter factor, its activator, inhibitors and the c-Met receptor in human cancer cells. Int. J. Oncol.2001, 19, 857–863.
83. Koga, F.; Tsutsumi S.; Neckers, L.M. Low dose geldanamycin inhibits hepatocyte growth factor and hypoxia-stimulated invasion of cancer cells. Cell. Cycle 2007, 6, 1393–1402.
84. Olaussen, K.A.; Commo, F.; Tailler, M.; Lacroix, L.; Vitale, I.; Raza, S.Q.; Richon, C.; Dessen, P.; Lazar, V.; Soria, J.C.; Kroemer, G. Synergistic proapoptotic effects of the two tyrosine kinase inhibitors pazopanib and lapatinib on multiple carcinoma cell lines. Oncogene2009, 28, 4249–4260.